Stephen Whitehead said:
"It is wonderful to see the Government’s Biomedical Catalyst initiative kick-off. This £10 million investment is only the start of a much bigger programme, but this really demonstrates the increased level of Government support for the UK life sciences industry.
“I’m delighted to see Government recognition for our colleagues in life sciences research. Universities and SMEs play a critical role in modern medical research, particularly at the early stages where the key discoveries are made. The pharmaceutical industry is changing to reflect the modern healthcare and research environment, and the universities and SMEs granted funds today, along with those that will receive awards in future, are among our key allies and partners in developing the next generation of medicines.”
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.